Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410630 · ClinicalTrials.gov registry record
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- 66
- Enrollment target
NCT01410630: Completed study, sponsored by Jonsson Comprehensive Cancer Center.
NCT01410630 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01410630 has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
Study Summary
A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorothymidine, which is taken up by cells that are actively proliferating or dividing such as cancer cells. We hope to learn whether this tracer is superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma (DLBCL).
Interventions
- DRUG FLT
- DIAGNOSTIC_TEST FLT-PET/CT
- DIAGNOSTIC_TEST FDG-PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2019-10-04 |
What the finished NCT01410630 record still lists
NCT01410630 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 66 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which FLT is the first listed.
NCT01410630 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01410630 about?
NCT01410630 is a clinical study titled "FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma". A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that yields better tracking of cancer treatment progress. PET/CT stands for positron emission tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT uses a new tracer, fluorot...
What is the current status of trial NCT01410630?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2017-09-07. Estimated completion is 2019-10-04.
What interventions are being tested in trial NCT01410630?
The interventions under investigation include: FLT (DRUG), FLT-PET/CT (DIAGNOSTIC_TEST), FDG-PET/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01410630?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI